Welcome to our dedicated page for Atea Pharmaceuticals SEC filings (Ticker: AVIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.
Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.
Atea Pharmaceuticals director Bruno Lucidi reported equity compensation activity centered on stock awards rather than open‑market trades. He exercised 29,600 restricted stock units into Common Stock and held 142,350 Common shares directly afterward. He also received 37,700 stock options with a $4.36 exercise price and 26,700 new restricted stock units, all subject to time‑based vesting over the coming year.
Atea Pharmaceuticals director Franklin M. Berger increased his equity exposure through compensation-related awards and an RSU vesting event. On June 18, 2026, 29,600 restricted stock units converted into an equal number of common shares, bringing his direct common stock holdings to 536,097 shares.
He also received a stock option for 37,700 shares at an exercise price of $4.36 per share, vesting in twelve equal monthly installments after June 18, 2026, and expiring on June 17, 2036. In addition, he was granted 26,700 new restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Howard Berman received new equity awards as part of his compensation. On June 18, 2026, he was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026, and are fully vested on June 18, 2027, if he continues serving the company.
He also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. The RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Barbara Gayle Duncan increased her equity stake through routine compensation-related transactions. On June 18, 2026, previously granted restricted stock units converted into 29,600 shares of common stock, bringing her direct holdings to 92,350 shares.
She also received new grants covering 37,700 stock options with a $4.36 exercise price, vesting in twelve equal monthly installments through June 18, 2027, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.
Atea Pharmaceuticals director Bruce Polsky reported routine equity compensation changes. On June 18, 2026, he exercised 29,600 restricted stock units into Common Stock at no cost, bringing his direct Common Stock holdings to 124,806 shares.
He also received new awards: a stock option for 37,700 shares of Common Stock at an exercise price of $4.36 per share, vesting in twelve equal monthly installments after June 18, 2026, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, in each case subject to continued service. The filing shows no share sales, only grants and exercises related to compensation.
Atea Pharmaceuticals director Polly A. Murphy reported equity compensation activity and an RSU vesting-related share delivery. On June 18, 2026, RSUs covering 29,600 shares of common stock were exercised into common stock, leaving her with 121,745 common shares directly held.
On the same date, she received a stock option grant for 37,700 shares of common stock at an exercise price of $4.36 per share, vesting in twelve substantially equal monthly installments through June 18, 2027, and expiring on June 17, 2036. She was also granted 26,700 restricted stock units, each representing one share of common stock, vesting in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.
Atea Pharmaceuticals director Jerome M. Adams reported equity compensation and a routine derivative exercise. On June 18, 2026, he exercised 29,600 shares of previously granted restricted stock units into Common Stock, leaving him with 92,350 Common shares held directly.
On the same date, he received a new grant of 37,700 stock options with a $4.36 exercise price, expiring on June 17, 2036, which vest in twelve equal monthly installments after June 18, 2026. He was also granted 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Arthur S. Kirsch received new equity awards. He was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026 and are fully vested by June 18, 2027, subject to his continued service.
Kirsch also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, conditioned on continued service through the vesting date.
Atea Pharmaceuticals reported results from its 2026 annual stockholder meeting. A total of 59,742,819 shares of common stock were represented, about 74.65% of shares outstanding as of the April 24, 2026 record date, indicating strong participation.
Stockholders elected three Class III directors—Jerome Adams, MD, MPH, Howard Berman, PhD, and Barbara Duncan—to serve until the 2029 annual meeting and until their successors are elected and qualified. They also ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the executive compensation program for the company’s named executive officers.
Atea Pharmaceuticals director Polly A. Murphy reported an open-market purchase of 6,100 shares of Common Stock on May 18, 2026 at a weighted average price of $4.1715 per share. Following this trade, she directly owns 92,145 shares of Atea Pharmaceuticals.
The shares were bought in multiple transactions at prices ranging from $4.14 to $4.19 per share. This Form 4/A amends a prior Form 4 only to correct the transaction date, which had been mistakenly reported as May 18, 2025 instead of May 18, 2026.